3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Gastrointestinal
2
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
5
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Blast Crisis
4
Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome
1
Neoplasms by Histologic Type
1
Myeloproliferative Disorders
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Glioblastoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Medullary
1
Carcinoma
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Interventions
Imatinib Mesylate
27
regorafenib
8
nilotinib
6
Sunitinib
6
pazopanib
3
Temozolomide
3
Paclitaxel
3
Nivolumab
3
Ipilimumab
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
trametinib
2
spartalizumab
2
ripretinib
2
ponatinib
2
envafolimab
2
Specimen Handling
2
Sorafenib
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Laparoscopy
2
Dasatinib
2
Carboplatin
2
CTLA-4 Antigen
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
vatalanib
1
temsirolimus
1
rubitecan
1
romidepsin
1
perifosine
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Stromal Tumors
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts
NCT03171389
2017-05-31
POETIG
Universität Duisburg-Essen
Phase 2
Unknown
81 enrolled